# LLM-Council Verdict — Manan vs Elicit

Judges: opus, codex, deepseek (cross-family: Anthropic Opus · OpenAI Codex · Google Gemini).
Manan run: `exact-title-fix` (current `main` HEAD, with the OpenAlex wildcard-400 fix and Cohere cross-encoder active).

## Per-query majority vote

| query | opus | codex | deepseek | **majority** | Manan mean | Elicit mean |
|---|---|---|---|---|---|---|
| tavr-low-risk-6yr | elicit | elicit | tie | **elicit** | 4.39 | 5 |
| exact-dapa-hf | manan | manan | manan | **manan** | 5 | 4.5 |
| recency-lecanemab | elicit | elicit | elicit | **elicit** | 4.17 | 5 |
| pico-sglt2-cv-mortality | elicit | elicit | manan | **elicit** | 4 | 4.17 |
| guideline-af-esc | manan | manan | manan | **manan** | 4.56 | 4.06 |
| compare-doac-vs-warfarin | tie | manan | manan | **manan** | 4.33 | 3.67 |

## Tally (by per-query majority)

- **Manan wins: 3**
- Elicit wins: 3
- Ties: 0

Overall winner per judge: opus=elicit, codex=manan, deepseek=manan.

## Judge summaries

- **opus:** Elicit wins the open-ended evidence-synthesis queries (TAVR long-term, lecanemab recency, SGLT2 PICO) by consistently surfacing the pivotal landmark RCTs and tightly on-topic syntheses, while Manan drifts into adjacent renal, device, or case-report material. Manan is genuinely competitive and wins the targeted retrieval tasks: it nails the exact DAPA-HF paper at #1 with a far stronger supporting set, and it uniquely includes the current 2024 ESC AF guideline that Elicit misses. Net result is three query wins for Elicit, two for Manan, and one tie, giving Elicit a narrow overall edge driven by superior precision on broad clinical questions.
- **codex:** Manan wins three queries and Elicit wins three, but Manan has stronger consistency across metadata completeness, guideline recency, and clinically useful evidence lists. Elicit is best when citation-heavy landmark retrieval matters, especially for exact landmark recall in TAVR and lecanemab.
- **deepseek:** Manan outperforms Elicit in 4 out of 6 queries, with one tie and one win for Elicit. Manan consistently provides more comprehensive, up-to-date, and clinically relevant results with better metadata and trustworthiness.

## Notes per query (first judge with a note)

- **tavr-low-risk-6yr:** Elicit surfaces both landmarks with PARTNER 3 (2019) at #1 and the Evolut 6-yr trial at #2, whereas Manan returns the Evolut 6-yr trial but omits the pivotal PARTNER 3 primary RCT and leads with meta-analyses.
- **exact-dapa-hf:** Both rank the verbatim DAPA-HF paper #1 correctly, but Manan's remaining nine are high-quality dapagliflozin/SGLT2i trials and meta-analyses while Elicit returns only three items, two of which are a low-value commentary and an appraisal.
- **recency-lecanemab:** Both lead with the CLARITY-AD trial at #1, but Elicit also captures the pivotal 36-month open-label extension (2025) and stays uniformly high-quality, while Manan misses that key recent follow-up and dilutes its top 10 with small case series, PET-imaging cohorts, and a tangential scoping review.
- **pico-sglt2-cv-mortality:** Elicit's results are all SGLT2i CV-outcome/mortality meta-analyses tightly matching the PICO outcome, whereas Manan drifts to renal/CKD outcomes, a HF trial, and an off-target GLP-1 oral-semaglutide analysis.
- **guideline-af-esc:** Both rank genuine ESC AF guidelines on top, but Manan uniquely includes the current 2024 ESC/EACTS guideline (#3) that Elicit omits entirely, despite one missing-ID and one off-topic supraventricular tail entry.
- **compare-doac-vs-warfarin:** Both lead with the COMBINE-AF patient-level network meta-analysis and the BMJ network MA yet neither surfaces the individual landmark RCTs; Manan drifts into device/periprocedural and factor-XIa entries while Elicit's #1 is a low-value 0-cite Journal Watch summary.